JP2017149720A5 - - Google Patents

Download PDF

Info

Publication number
JP2017149720A5
JP2017149720A5 JP2017047055A JP2017047055A JP2017149720A5 JP 2017149720 A5 JP2017149720 A5 JP 2017149720A5 JP 2017047055 A JP2017047055 A JP 2017047055A JP 2017047055 A JP2017047055 A JP 2017047055A JP 2017149720 A5 JP2017149720 A5 JP 2017149720A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
amino acid
constant region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017047055A
Other languages
English (en)
Japanese (ja)
Other versions
JP6513728B2 (ja
JP2017149720A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017149720A publication Critical patent/JP2017149720A/ja
Publication of JP2017149720A5 publication Critical patent/JP2017149720A5/ja
Application granted granted Critical
Publication of JP6513728B2 publication Critical patent/JP6513728B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017047055A 2011-11-23 2017-03-13 Ｈｅｒ３に特異的な結合分子及びそれらの使用 Active JP6513728B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161563092P 2011-11-23 2011-11-23
US61/563,092 2011-11-23
US201261656670P 2012-06-07 2012-06-07
US61/656,670 2012-06-07
US201261722558P 2012-11-05 2012-11-05
US61/722,558 2012-11-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014543533A Division JP6180425B2 (ja) 2011-11-23 2012-11-20 Ｈｅｒ３に特異的な結合分子及びそれらの使用

Publications (3)

Publication Number Publication Date
JP2017149720A JP2017149720A (ja) 2017-08-31
JP2017149720A5 true JP2017149720A5 (enExample) 2017-10-26
JP6513728B2 JP6513728B2 (ja) 2019-05-15

Family

ID=48470246

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014543533A Active JP6180425B2 (ja) 2011-11-23 2012-11-20 Ｈｅｒ３に特異的な結合分子及びそれらの使用
JP2017047055A Active JP6513728B2 (ja) 2011-11-23 2017-03-13 Ｈｅｒ３に特異的な結合分子及びそれらの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014543533A Active JP6180425B2 (ja) 2011-11-23 2012-11-20 Ｈｅｒ３に特異的な結合分子及びそれらの使用

Country Status (17)

Country Link
US (3) US9220775B2 (enExample)
EP (2) EP2797957B1 (enExample)
JP (2) JP6180425B2 (enExample)
KR (1) KR102080535B1 (enExample)
CN (2) CN108424456B (enExample)
AU (1) AU2012340766B2 (enExample)
BR (1) BR112014012539B1 (enExample)
CA (1) CA2856297C (enExample)
CO (1) CO7051008A2 (enExample)
DK (1) DK2797957T3 (enExample)
ES (1) ES2745684T3 (enExample)
IL (1) IL232726B2 (enExample)
MX (1) MX350957B (enExample)
RU (1) RU2620068C2 (enExample)
SG (1) SG11201402536PA (enExample)
WO (1) WO2013078191A1 (enExample)
ZA (1) ZA201403570B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012340766B2 (en) 2011-11-23 2018-05-10 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
AU2012349735B2 (en) * 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
ES2816624T3 (es) 2014-02-28 2021-04-05 Merus Nv Anticuerpos que se unen a EGFR y ERBB3
HRP20250041T1 (hr) * 2014-02-28 2025-03-14 Merus N.V. Antitijelo koje veže erbb-2 i erbb-3
WO2015150826A1 (en) * 2014-04-04 2015-10-08 Astrazeneca Ab Combination of egfr inhibitor and mek inhibitor for use in the treatment of nras mutated cancer
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
US20170190788A1 (en) * 2014-09-11 2017-07-06 Bulldog Pharmaceuticals, Inc. Uses of anti-her3 antibodies for treating cancer
WO2016168634A1 (en) * 2015-04-17 2016-10-20 Bulldog Pharmaceuticals, Inc. Biomarkers related to treatment of cancer with her3 and egfr inhibitors
TW201716439A (zh) 2015-07-20 2017-05-16 美國禮來大藥廠 Ｈｅｒ３抗體
KR20250157457A (ko) 2015-10-23 2025-11-04 메뤼스 엔.페. 암 성장을 억제하는 결합 분자
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
JP2019508428A (ja) 2016-03-15 2019-03-28 メリマック ファーマシューティカルズ インコーポレーティッド 抗ｅｒｂｂ３抗体を含む組み合わせ療法を用いて、ｅｒ＋、ｈｅｒ２−、ｈｒｇ＋乳癌を治療するための方法
KR101796684B1 (ko) 2016-05-19 2017-11-10 건국대학교 산학협력단 케라틴 8 인산화 억제제를 포함하는 황반변성 예방 또는 치료용 약학 조성물 및 황반변성 치료제의 스크리닝 방법
BR112019015915A2 (pt) * 2017-02-28 2020-04-07 Daiichi Sankyo Co Ltd método para o tratamento de câncer de pulmão de células não pequenas resistentes a egfr-tki através da administração do conjugado de anticorpo anti-her3-fármaco
WO2018182422A1 (en) 2017-03-31 2018-10-04 Merus N.V. Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
CN111148764B (zh) 2017-05-17 2025-08-12 美勒斯公司 用于乳腺癌的ErbB-2/ErbB-3双特异性抗体与内分泌治疗的组合
PL3665198T3 (pl) 2017-08-09 2025-06-09 Merus N.V. Przeciwciała wiążące egfr i cmet
CN110724194B (zh) * 2018-07-17 2021-03-19 上海生物制品研究所有限责任公司 抗her3人源化单克隆抗体及其制剂
IL281344B2 (en) 2018-09-10 2025-09-01 Mirati Therapeutics Inc Combination of adagrasib and cetuximab for cancer treatment
CN110760003A (zh) * 2019-09-10 2020-02-07 广东药科大学 一种抗her3单链抗体的制备方法
US20220401580A1 (en) * 2019-11-12 2022-12-22 University Of Virginia Patent Foundation Optidicer construct for age-related macular degeneration
AU2023228226A1 (en) * 2022-03-03 2024-10-03 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Her3 binding protein and use thereof
JP2025535442A (ja) * 2022-10-19 2025-10-24 マルチチュード・セラピューティックス・インコーポレーテッド 抗体－薬物コンジュゲート、その調製方法、および、その抗腫瘍への使用

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3588239T3 (de) 1985-03-30 2007-03-08 Kauffman, Stuart A., Santa Fe Verfahren zum Erhalten von DNS, RNS, Peptiden, Polypeptiden oder Proteinen durch DMS-Rekombinant-Verfahren
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FI915411A0 (fi) 1989-05-16 1991-11-15 Scripps Research Inst Samexpression av heteromeriska receptorer.
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
IL126303A (en) 1996-03-27 2002-05-23 Genentech Inc ErbB3 ANTIBODIES
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US5804968A (en) 1997-01-29 1998-09-08 Picker International, Inc. Gradient coils with reduced eddy currents
US20030105057A1 (en) 1997-03-19 2003-06-05 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
PT998486E (pt) 1997-06-13 2007-08-21 Genentech Inc ''recuperação de proteínas por cromatografia seguida de filtração numa camada carregada''
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
RU2270029C2 (ru) 1999-06-25 2006-02-20 Джинентех, Инк. ГУМАНИЗИРОВАННОЕ АНТИТЕЛО, КОТОРОЕ ОБЛАДАЕТ СПОСОБНОСТЬЮ СВЯЗЫВАТЬ ErbB2 И БЛОКИРОВАТЬ АКТИВАЦИЮ ЛИГАНДОМ РЕЦЕПТОРА ErbB (ВАРИАНТЫ) И КОМПОЗИЦИЯ ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ РАКА, СОДЕРЖАЩАЯ ЭТО АНТИТЕЛО
WO2001002588A2 (en) 1999-07-02 2001-01-11 Morphosys Ag Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
US7390632B2 (en) 1999-09-30 2008-06-24 Tumor Biology Investment Group, Inc. Soluble ErbB3 receptor isoforms
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
PT1282443E (pt) 2000-05-19 2009-12-04 Genentech Inc Análise de detecção génica para melhorar a probabilidade de uma resposta eficaz a uma terapia do cancro com um antagonista de erbb
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
EP1228766A1 (en) 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
US20040138160A1 (en) 2001-04-27 2004-07-15 Kenichiro Naito Preventive/therapeutic method for cancer
US20040116330A1 (en) 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
US7612042B2 (en) 2001-05-31 2009-11-03 Tumor Biology Investment Group, Inc. Methods for inhibiting heregulin and treating cancer
US7744882B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 methods of detection and antibodies
ATE535258T1 (de) 2001-06-01 2011-12-15 Cornell Res Foundation Inc Modifizierte antikörper gegen prostata- spezifisches membranantigen und ihre verwendungen
JP4298498B2 (ja) 2001-06-13 2009-07-22 ゲンマブ エー／エス 上皮成長因子受容体（ｅｇｆｒ）に対するヒトモノクローナル抗体
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2003011897A1 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Modulation of heregulin and her3 interaction
US7662374B2 (en) 2001-08-03 2010-02-16 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbB family members and methods of use thereof
EP1283053A1 (en) * 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
ATE417858T1 (de) 2002-02-05 2009-01-15 Genentech Inc Proteinaufreinigung
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
DE60330227D1 (de) 2002-03-13 2010-01-07 Array Biopharma Inc N3-alkylierte benzimidazol-derivate als mek-hemmer
AU2003218600C1 (en) 2002-03-26 2009-12-17 Zensun (Shanghai) Science & Technology Co., Ltd. ERBB3 based methods and compositions for treating neoplasms
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
AU2003265235A1 (en) 2002-04-26 2003-12-19 Genetech, Inc. Non-affinity purification of proteins
US20040229299A1 (en) 2002-05-21 2004-11-18 Badal M. Youssouf Intracellular complexes as biomarkers
US20040229380A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US20040229293A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui Surface receptor complexes as biomarkers
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
AT413486B (de) 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
EP2263691B1 (en) * 2002-07-15 2012-08-29 F.Hoffmann-La Roche Ag Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
WO2004012769A1 (en) 2002-08-02 2004-02-12 The Regents Of The University Of California Therapeutic inhibitionof protein kinases in cancer cells
AU2003264488A1 (en) 2002-09-19 2004-04-08 Orient Cancer Therapy Co., Ltd. Immunotherapeutic for cancer
DK1578446T3 (en) 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
US7575893B2 (en) 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
WO2004076621A2 (en) 2003-02-27 2004-09-10 Yeda Research And Development Co. Ltd. Compositions of nucleic acids for treating and detecting influenza virus
EP1613273B1 (en) 2003-04-11 2012-06-13 MedImmune, LLC Recombinant il-9 antibodies and uses thereof
TW568408U (en) 2003-05-14 2003-12-21 High Tech Comp Corp Slide structure
CN1972712A (zh) 2003-06-09 2007-05-30 塞缪尔·瓦克萨尔 用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法
EP1493445A1 (en) 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
PT3095793T (pt) 2003-07-28 2020-05-04 Genentech Inc Redução da lixiviação de proteína a durante a cromatografia por afinidade com proteína a
WO2005011607A2 (en) 2003-08-01 2005-02-10 Smithkline Beecham Corporation Treatment of cancers expressing p95 erbb2
BRPI0416190A (pt) 2003-11-06 2007-01-23 Pfizer Prod Inc combinações selectivas de inibidor erbb2/anticorpo anti erbb no tratamento do cancro
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
WO2005099756A2 (en) 2004-04-08 2005-10-27 Agus David B ErbB ANTAGONISTS FOR PAIN THERAPY
JP2007536254A (ja) 2004-05-05 2007-12-13 メリマック ファーマシューティカルズ インコーポレーティッド 生物活性を調節するための二重特異性結合剤
EP1685161A1 (en) 2004-08-30 2006-08-02 Lonza Biologics plc Affinity- plus ion exchange-chromatography for purifying antibodies
EP1807106A2 (en) 2004-10-05 2007-07-18 Oregon Health and Science University Compositions and methods for treating disease
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20070009972A1 (en) 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
DK1850874T3 (da) 2005-02-23 2013-11-11 Genentech Inc Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab
AU2006220719A1 (en) 2005-03-07 2006-09-14 Ligacept, Llc Tyrosine kinase inhibitor compositions and methods for manufacturing and using them in the treatment of disease
WO2006133460A2 (en) 2005-06-09 2006-12-14 Yale University Methods for diagnosing and treating breast cancer based on a her/er ratio
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
CN101309933A (zh) * 2005-09-07 2008-11-19 米迪缪尼有限公司 毒素偶联的Eph受体抗体
AU2006287416A1 (en) * 2005-09-07 2007-03-15 Medimmune, Llc Toxin conjugated Eph receptor antibodies
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
WO2007077435A1 (en) 2005-12-30 2007-07-12 Astex Therapeutics Limited Pharmaceutical compounds
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
EP2049568A2 (en) 2006-04-07 2009-04-22 Københavns Universitet Erbb receptor-derived peptide fragments
CA2639070A1 (en) 2006-04-13 2007-11-01 Oncomethylime Sciences S.A. Novel tumour suppressor
US8580263B2 (en) 2006-11-21 2013-11-12 The Regents Of The University Of California Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
US20100047829A1 (en) 2006-11-28 2010-02-25 U3 Pharma Gmbh Activated her3 as a marker for predicting therapeutic efficacy
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US7825127B2 (en) 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
WO2008081331A2 (en) 2006-12-29 2008-07-10 Sinomab Bioscience Limited Enhancing the level of antibody expression by framework re-engineering
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
PL2129396T3 (pl) 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania
BRPI0808418A2 (pt) 2007-03-02 2014-07-22 Genentech, Inc Predição de resposta a um inibidor de her
ES2407957T3 (es) 2007-03-09 2013-06-17 Geron Corporation Tratamiento de carcinomas con una combinación de inhibidores de la vía EGF y de la telomerasa
EP2139924B1 (en) 2007-03-29 2016-07-06 Genmab A/S Bispecific antibodies and methods for production thereof
ES2529790T3 (es) 2007-04-13 2015-02-25 Dana-Farber Cancer Institute, Inc. Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
US20090258005A1 (en) 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
WO2009052830A1 (en) 2007-10-22 2009-04-30 Genmab A/S Novel antibody therapies
CN101970490A (zh) * 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
WO2009092014A1 (en) 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of antibodies and antibody fragments by apatite chromatography
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
EP2281575B9 (en) 2008-04-09 2014-02-12 Universidad de Barcelona Antibodies for treating cancer
EA022201B1 (ru) 2008-04-11 2015-11-30 Мерримак Фармасьютикалз, Инк. Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение
WO2009157919A1 (en) 2008-06-23 2009-12-30 Tumor Biology Investment Group, Inc. SOLUBLE ErbB3 DETECTION, REGULATION AND TREATMENT OF CANCER
EP2138511A1 (en) * 2008-06-27 2009-12-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. HER3 as a determinant for the prognosis of melanoma
EP2159836B1 (en) 2008-08-25 2017-05-31 Soitec Stiffening layers for the relaxation of strained layers
KR20110086844A (ko) 2008-11-07 2011-08-01 엔즌 파마슈티칼스, 인코포레이티드 Ｅｒｂｂ－３（ｈｅｒ３）－선택적 조합 요법
US20110020327A1 (en) 2008-12-16 2011-01-27 Millipore Corporation Purification of proteins
CA2753119A1 (en) 2009-02-24 2010-09-02 F. Hoffmann-La Roche Ag Use of s-erbb-3 as a marker for cancer
NZ594665A (en) 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
AU2010242914B2 (en) 2009-04-29 2014-11-13 Trellis Bioscience, Llc Improved antibodies immunoreactive with heregulin-coupled HER3
EP2448599A1 (en) 2009-06-30 2012-05-09 Philogen S.p.A. Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer
US20110039300A1 (en) 2009-08-10 2011-02-17 Robert Bayer Antibodies with enhanced adcc functions
CA2775573A1 (en) * 2009-10-09 2011-04-14 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her 3 antibodies
CA2777242A1 (en) 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
KR101806323B1 (ko) 2009-11-13 2017-12-07 다이이치 산쿄 유럽 게엠베하 Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법
CA2782571C (en) * 2009-12-22 2018-01-23 Roche Glycart Ag Anti-her3 antibodies and uses thereof
US8895001B2 (en) 2010-03-11 2014-11-25 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
BR112012025730B1 (pt) 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
WO2011153383A1 (en) 2010-06-04 2011-12-08 Bipar Science, Inc. Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
JP2013540694A (ja) 2010-08-06 2013-11-07 ウー３・フアルマ・ゲー・エム・ベー・ハー Ｈｅｒ３結合剤の前立腺治療における使用
PL2606070T3 (pl) 2010-08-20 2017-06-30 Novartis Ag Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
WO2012052230A1 (en) 2010-10-18 2012-04-26 Mediapharma S.R.L. Erbb3 binding antibody
EP3156421B1 (en) 2010-11-01 2018-06-06 Symphogen A/S Pan-her antibody composition
US20150231238A1 (en) 2011-03-15 2015-08-20 Merrimack Pharmaceuticals, Inc. Overcoming resistance to erbb pathway inhibitors
AU2012274461A1 (en) 2011-06-20 2014-01-16 Kyowa Hakko Kirin Co., Ltd. Anti-erbB3 antibody
CA2849508C (en) 2011-09-30 2020-12-22 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
CA2855298A1 (en) 2011-11-09 2013-05-16 The Uab Research Foundation Her3 antibodies and uses thereof
AU2012340766B2 (en) 2011-11-23 2018-05-10 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
AU2012349735B2 (en) 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
HK1206645A1 (en) 2012-03-29 2016-01-15 Shire Human Genetic Therapies, Inc. Ionizable cationic lipids
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
US11305012B2 (en) * 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
US10745490B2 (en) * 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
US20170190788A1 (en) 2014-09-11 2017-07-06 Bulldog Pharmaceuticals, Inc. Uses of anti-her3 antibodies for treating cancer
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Similar Documents

Publication Publication Date Title
JP2017149720A5 (enExample)
JP2015506912A5 (enExample)
KR102078292B1 (ko) 신규한 항 c-Met 항체 및 이의 용도
RU2014120757A (ru) Связывающие молекулы, специфичные по отношению к her3, и их применения
CN103260646B (zh) Notum蛋白调节剂和使用方法
IL276830B2 (en) Anti-claudin 18.2 antibodies and uses thereof
JP2023525827A (ja) 抗ｃｄ７３抗体およびその使用
JP2020514277A5 (enExample)
KR20160070191A (ko) 신규한 항-클라우딘 항체 및 사용 방법
JP2019532619A5 (enExample)
JP2016526904A5 (enExample)
JP2017535257A5 (enExample)
HK1215035A1 (zh) 人源化抗cd134(ox40)抗體及其應用
JP2018502050A5 (enExample)
RU2016137110A (ru) Антитела к компоненту комплемента с5
JP2017512765A5 (enExample)
JP2017535257A (ja) 免疫応答およびがん治療の増強に使用するための組成物および方法
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
CN106459212A (zh) 结合erbb‑2和erbb‑3的抗体
CN112513094A (zh) 结合人her2的抗体、其制备方法和用途
WO2014185704A1 (ko) Her2에 특이적으로 결합하는 항체
JP7328324B2 (ja) Ｔｉｍ－３に対する抗体およびその使用
CA3193584A1 (en) Nectin-4 antibodies and uses thereof
JP2020521504A (ja) 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
TW202241944A (zh) 新穎的抗ｇｒｅｍｌｉｎ１抗體